ESTA icon

Establishment Labs

33.43 USD
-1.60
4.57%
At close Feb 21, 4:00 PM EST
After hours
33.00
-0.43
1.29%
1 day
-4.57%
5 days
-2.19%
1 month
-5.99%
3 months
-21.54%
6 months
-24.11%
Year to date
-26.17%
1 year
-6.62%
5 years
39.82%
10 years
35.07%
 

About: Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing silicone-filled breast and body shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.

Employees: 933

0
Funds holding %
of 7,139 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

137% more call options, than puts

Call options by funds: $66M | Put options by funds: $27.9M

92% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 26

14% more funds holding in top 10

Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]

12% more capital invested

Capital invested by funds: $1.08B [Q3] → $1.22B (+$133M) [Q4]

2.21% more ownership

Funds ownership: 89.67% [Q3] → 91.89% (+2.21%) [Q4]

9% less funds holding

Funds holding: 129 [Q3] → 118 (-11) [Q4]

28% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 29

Research analyst outlook

We haven’t received any recent analyst ratings for ESTA.

Financial journalist opinion

Based on 3 articles about ESTA published over the past 30 days

Neutral
Business Wire
1 day ago
Establishment Labs to Present at Citi's 2025 Unplugged Medtech and Life Sciences Access Day
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in a fireside chat at Citi's 2025 Unplugged Medtech and Life Sciences Access Day. Juan José Chacón-Quirós, Chief Executive Officer and Founder; Peter Caldini, President; and Raj Denhoy, Chief Financial Officer, are scheduled to present on Thursday,.
Establishment Labs to Present at Citi's 2025 Unplugged Medtech and Life Sciences Access Day
Neutral
Business Wire
4 days ago
Establishment Labs Launches Preservé™
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced it has launched Preservé™ in Brazil, the first country in its global rollout. Preservé is the second product in the Company's minimally invasive platform, building upon the technologies and techniques developed with Mia Femtech®, Establishment Labs' minimally invasive experience. “The.
Establishment Labs Launches Preservé™
Neutral
Business Wire
1 week ago
Establishment Labs to Announce Fourth Quarter 2024 Financial Results on February 26
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2024, after the market closes on Wednesday, February 26, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S.
Establishment Labs to Announce Fourth Quarter 2024 Financial Results on February 26
Neutral
Business Wire
1 month ago
Establishment Labs Announces CEO Transition
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Mr. Chacón-Quirós will continue with Esta.
Establishment Labs Announces CEO Transition
Neutral
Business Wire
1 month ago
Establishment Labs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 3:45 p.m. Pacific Time. A live webcast of the presentation.
Establishment Labs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Neutral
Business Wire
3 months ago
Establishment Labs Announces Participation in Upcoming Investment Conferences
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in three upcoming investment conferences. Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in the 2024 UBS Global Healthcare Conference being held November 11-14, 2024. Mr. Chac.
Establishment Labs Announces Participation in Upcoming Investment Conferences
Neutral
Seeking Alpha
3 months ago
Establishment Labs Holdings Inc. (ESTA) Q3 2024 Earnings Call Transcript
Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Rajbir Denhoy - Chief Financial Officer Juan Jose - CEO and Founder Conference Call Participants Allen Gong - JPMorgan Matt Taylor - Jefferies Sam Eiber - BTIG Anthony Pettinari - Citi Josh Jennings - TD Cowen Anthony Petrone - Mizuho Group Operator Good afternoon. Welcome to Establishment Labs Third Quarter 2024 Earnings Conference Call.
Establishment Labs Holdings Inc. (ESTA) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
3 months ago
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Misses Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $1.12 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Misses Revenue Estimates
Neutral
Business Wire
3 months ago
Establishment Labs Announces $50 Million Registered Direct Offering
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with select purchasers for the purchase of 765,696 common shares and pre-funded warrants to purchase up to 328,161 common shares in a registered direct offering for a.
Establishment Labs Announces $50 Million Registered Direct Offering
Neutral
Business Wire
3 months ago
Establishment Labs Reports Third Quarter 2024 Financial Results
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2024. Third Quarter Highlights and Outlook Third quarter worldwide revenue of $40.2 million. 2024 revenue guidance updated to $165 million to $168 million from previous guidance of $174 million to $184 mill.
Establishment Labs Reports Third Quarter 2024 Financial Results
Charts implemented using Lightweight Charts™